Amodiaquine Antibody (6F21): sc-70349

Amodiaquine Antibody (6F21) is a mouse monoclonal IgG2a antibody that detects Amodiaquine in non-species reactive samples by enzyme-linked immunosorbent assay (ELISA). Amodiaquine is a 4-aminoquinoline compound known for its antimalarial properties, functioning primarily by accumulating in the lysosomes of parasites, which leads to a loss of function and ultimately cell death. This mechanism is crucial as it disrupts the parasite′s ability to metabolize heme, resulting in the accumulation of toxic free heme, which is detrimental to the survival of the malaria-causing organisms. The ability of Amodiaquine to inhibit heme polymerase activity is particularly significant, as this action targets the metabolic pathways of parasites, making Amodiaquine an effective treatment option for malaria. Amodiaquine has been utilized for over 40 years not only as an antimalarial agent but also for its anti-inflammatory properties, showcasing versatility in therapeutic applications. However, caution is advised, as an overdose can lead to severe side effects, including cardiovascular and respiratory complications. Anti-Amodiaquine antibody (6F21) serves as an essential tool for researchers studying the effects and mechanisms of Amodiaquine in various biological contexts.

The preferred Amodiaquine antibody is Amodiaquine Antibody (6D10): sc-80638.